Clinical Significance of B7‐H4 in Peripheral Blood of Patients With Myasthenia Gravis
Journal of Immunology Research · 2026-01 · 2026 (1)
DOI: 10.1155/jimr/2743928 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology Research, online erschienen am 09.05.2026. Verfasst von Xiaoling Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China, sdfyy.cn. Hauptthemen laut MEDLINE: Myasthenia Gravis, V-Set Domain-Containing T-Cell Activation Inhibitor 1. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Soochow University Collaborative Innovation Center Research Project, The First Affiliated Hospital of Soochow University Clinical Diagnosis and Treatment Technology Innovation Program.
Abstract (Originalsprache)
Objectives
This study aimed to systematically investigate the dynamics changes in membrane‐bound B7‐H4 (mB7‐H4) expression and soluble B7‐H4 (sB7‐H4) levels in the peripheral blood of patients with acetylcholine receptor antibodies (AchR‐Ab)‐positive myasthenia gravis (MG) across different disease phases, and to explore their clinical significance.
Methods
AchR‐Ab‐positive MG patients at baseline, relapse, and remission stages, along with age‐ and sex‐matched healthy controls (HCs), were enrolled. Peripheral blood was obtained from all participants. mB7‐H4 expression on circulating immune cell subsets was determined by flow cytometry, while plasma sB7‐H4 concentration was quantified using enzyme‐linked immunosorbent assay (ELISA).
Results
Compared to HC, patients with relapsing MG exhibited significantly increased mB7‐H4 expression on CD4 + T cells and CD14 + monocytes ( p < 0.05). In contrast, plasma sB7‐H4 levels were markedly decreased in relapsing‐MG patients relative to HC ( p < 0.05). Among MG subgroups, mB7‐H4 expression on CD4 + T cells was significantly higher in relapsing‐MG patients than in those at baseline or in remission ( p < 0.05). Conversely, plasma sB7‐H4 levels were significantly lower in both relapsing and remitting patients compared with the baseline‐MG group ( p < 0.05). Within the relapsing‐MG patients, patients with abnormal thymic pathology exhibited significantly lower sB7‐H4 levels than those with a normal thymus ( p < 0.05). Correlation analyses demonstrated that mB7‐H4 expression on CD14 + monocytes was positively correlated with quantitative MG scores (QMGs; r = 0.544, p = 0.020), whereas sB7‐H4 levels were negatively correlated with QMGs ( r = −0.417, p = 0.016). Immunosuppressive treatment did not significantly affect sB7‐H4 levels compared with pre‐treatment values ( p > 0.05). Univariate analysis identified elevated mB7‐H4 expression on CD4 + T cells as a potential risk factor for MG relapse. However, this association did not remain significant after multivariate adjustment for confounders variables.
Conclusions
During MG relapse, inflammatory activation may engage the B7‐H4 pathway, characterized by increased mB7‐H4 and decreased sB7‐H4 levels, which may cooperatively contribute to immune suppression and serve as a compensatory protective mechanism. B7‐H4 expression appears to be associated with disease severity. Thymic abnormalities may contribute to the downregulation of sB7‐H4, whereas immunosuppressive treatment may not significantly modify its circulating levels. Although increased CD4 + B7‐H4 expression is associated with relapse, it does not represent an independent predictor of relapse risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China, sdfyy.cn.
- Institute of Clinical Immunology, Jiangsu Key Laboratory of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China, sdfyy.cn.
- Department of Neurology, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215123, Jiangsu, China.
- Department of Neurology, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, 530021, Guangxi, China, gxhospital.com.
ORCID-Profile: Xiaoling Zhou, Yunfei Zhu, Jingluan Tian, Qun Xue
Förderung
- National Natural Science Foundation of China
- Soochow University Collaborative Innovation Center Research Project
- The First Affiliated Hospital of Soochow University Clinical Diagnosis and Treatment Technology Innovation Program
Zitieren
APA
Zhou, X., Zhu, Y., Gui, T., Gu, Y., Lu, H., Ju, W., Tian, J., & Xue, Q. (2026). Clinical Significance of B7‐H4 in Peripheral Blood of Patients With Myasthenia Gravis. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/2743928
Vancouver
Zhou X, Zhu Y, Gui T, Gu Y, Lu H, Ju W, et al. Clinical Significance of B7‐H4 in Peripheral Blood of Patients With Myasthenia Gravis. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/2743928
BibTeX
@article{Zhou2026,
author = {Zhou, Xiaoling and Zhu, Yunfei and Gui, Tiantian and Gu, Yanzheng and Lu, Haifeng and Ju, Wentong and Tian, Jingluan and Xue, Qun},
title = {Clinical Significance of B7‐H4 in Peripheral Blood of Patients With Myasthenia Gravis},
journal = {Journal of Immunology Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jimr/2743928}
}
EUVIMED